Oncologic Impact of Renal Tissue Adjacent to Renal Cell Carcinoma

STEFAN AUFDERKLAMM¹, JÖRG HENNENLOTTER¹, TILMAN TODENHÖFER¹, NICOLAS SENGHAAS¹, MARCUS SCHARPF², GEORGIOS GAKIS¹, STEFFEN RAUSCH¹, JOHANNES MISCHINGER¹, SIMONE BIER¹, ARNULF STENZL¹, CHRISTIAN SCHWENTNER³ and JENS BEDKE¹

¹Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany; ²Department of Pathology, Eberhard Karls University Tübingen, Tübingen, Germany; ³Department of Urology, Diakonie Klinikum Stuttgart, Stuttgart, Germany

Abstract. Aim: The aim of the study was to investigate the clinical impact of the surgical margin width after nephronsparing surgery (NSS) on the oncological course of renal cell carcinoma (RCC). Patients and Methods: The study comprised of 126 RCC patients with NSS between 2002 and 2009. Inclusion criteria were negative resection margins and a tumor diameter of ≤100 mm with the possibility of a complete circumferential histopathological reevaluation. The minimal benign margin width was correlated to the patients' clinical course. Results: Median safety margin width was revealed to be 1 mm. Nine of 126 patients (7.1%) developed recurrent disease (five local, four distant). All patients with local recurrence had safety margins ≤1 mm, whereas out of 49 patients with a margin >1 mm no one developed local recurrence (p=0.0245). Safety margin ≤ 1 mm showed associations with increased risk for overall recurrence in univariate and multivariate analysis (p=0.0531 and 0.0539, respectively). Conclusion: Tumor adjacent renal parenchyma may have oncological relevance, corroborating the need for further molecular investigation of tumor-adjacent tissue in RCC.

In renal cell cancer nephron sparing surgery (NSS) techniques have always considered a significant safety margin to be mandatory to minimize the risk for local recurrence (1, 2). Nowadays simple enucleation of the renal mass with an intact capsule is generally considered to be sufficient for oncological control comparable to radical nephrectomy in renal cell carcinoma (RCC) (2, 3).

Correspondence to: Prof. Dr. Jens Bedke, MD, Department of Urology, Eberhard-Karls University Tübingen, Hoppe-Seyler Strasse 3, D-72076 Tübingen, Germany. Tel: +49 70712987222, Fax: +49 7071295092, e-mail: jens.bedke@med.uni-tuebingen.de

Key Words: Renal cell carcinoma, nephron-sparing surgery, parenchyma, safety margin, recurrence, oncological outcome.

However, the relevance of suspected premalignant conditions within healthy-looking renal tissue outside the pseudocapsule still remains unclear. Histopathological data showed cancer foci in 39% of T1b tumors beyond the pseudocapsule within 3 mm of the primary tumor (4) and the significance of these lesions cannot not be yet sufficiently determined. Tumor heterogeneity studies revealed higher tumor aggressiveness in peripheral tumor areas compared to the central zone (5) and even provide evidence for molecularly altered tumor-adjacent healthy tissue in several urological cancers (6, 7). The fact that histologically, renal parenchymal tissue may already possess molecular alterations associated with malignancy raises the question whether these areas may influence the clinicopathological course of RCC after partial resection. The aim of the present study was to investigate the hypothesis of a possible oncological impact of adjacent benign renal tissue by the assessment of the individual safety margin width and to compare the clinical course of RCC patients after NSS.

Patients and Methods

The study comprised of 126 patients with histopathologically confirmed RCC and NSS diagnosed between 2002 and 2009 with histologically-negative surgical margins and with the possibility of a complete circumferential histopathological reevaluation (Figure 1A-B). Patients with previous surgery for RCC, positive resection margins, tumor diameter >100 mm or incomplete follow-up were excluded from the analysis. Institutional review board approval had been obtained prior to data analysis (No. 123/2013 BO2). Table I shows patients' characteristics of the whole cohort as well as of subgroups with margin widths ≤1 mm and >1 mm, respectively.

The width of the respective safety margin of renal parenchyma adjacent to the tumor was assessed histopathologically and measured circumferentially by means of a microscopic scale on H&E stained slides. As 'margin width' the minimal distance between areas showing RCC and the external border of the benign renal tissue was defined. These margins consisted of either the tumor capsule plus few cell layers or of additional renal parenchyma

0250-7005/2016 \$2.00+.40

of a varying extent (Figure 1C-F). First benign margin widths were re-evaluated and classified microscopically into sub-groups of margin ≤ 1 mm, >1 to ≤ 2 mm, >2 to ≤ 3 mm, >3 to ≤ 4 mm, >4 to ≤ 5 mm and >5mm. Afterwards the cohort was subdivided by the median margin width.

All patients were monitored postoperatively according to the European Association of Urology Guidelines by computed tomography or magnetic resonance imaging. Clinical course was assessed and time to recurrence, cancer specific (CCS) and overall survival (OS) were determined. Individual margin width was correlated to clinical data by Chi-square and Wilkoxon/Kruskal-Wallis-tests and by univariate and multivariate Cox proportional hazard analysis including T-stage and tumor grading. JMP 7.0® (SAS Inc., Cary, NC, USA) software was used for analysis.

Results

Patients' characteristics are summarized in Table I. The study included 34 female and 92 male patients (27.0% and 73.0%). Median age was 65 years (range 17-82 years). The surgical approach was open in 86 and laparoscopy in 40 cases (68.3% and 31.7%). Most common histology was clear cell (cc)RCC (84; 66.7%). No affected lymph nodes were known at time of surgery. In one patient (0.8%) a singular sternal metastasis was known at time of surgery and resected immediately after partial nephrectomy. The patient did not develop any tumor recurrence within the observation period. Median follow-up was 65.5 months (range=1-116 months).

All specimens were microscopically re-evaluated to exclude positive surgical margins and the pseudocapsule showed complete integrity in all included specimen.

The median histopathological parenchymal margin width was 1 mm (range <1-13 mm). Margin widths distributed as follows: ≤ 1 mm (77, 61.1%), >1 to ≤ 2 mm (20, 15.8%), >2 to ≤ 3 mm (13, 10.3%), >3 to ≤ 4 mm (5, 4.0%), >4 to ≤ 5 mm (5, 4.0%), >5mm (6, 4.8%).

The cohort was then subdivided by the median margin width. There were no statistical differences between these subgroups, 'margin ≤1 mm' and 'margin >1 mm' (Table I). Notably, there was no difference in subtype distribution between patients with safety margins of ≤1 and >1 mm (Table I). Nine of 126 patients had local or distant disease relapse (7.1%). In five patients (4.0%) the recurrent lesion was in the formerly treated kidney whereas it was systemic in four patients (3.2%). The patient with the initially diagnosed sternal metastasis did not develop local or distant recurrent disease within the observation period. Initial histology of the five patients with local recurrence revealed ccRCC in four and papillary (pap)RCC in one patient. Initial T-stages were pT1a in one patient, pT1b and pT3a in two patients, respectively. The median tumor diameter was 28 mm (range=8-63 mm) (Table III). In case of a secondary surgery due to tumor recurrence all histological reports revealed the same tumor entity as in the primarily performed NSS. All five patients with locally recurrent disease had a

Table I. Patients' characteristics of the study cohort and the subgroups showing margin width ≤ 1 and > 1 mm, respectively.

| Variables | All patients | Saftey margin ≤1 mm | Saftey margin >1 mm | <i>p</i> -Value |
|---------------------|--------------|---------------------------|---------------------------|-----------------|
| Patients - n (%) | 126 (100) | 77 (61.1) | 49 (38.9) | |
| Gender - n (%) | | | | 0.5722 |
| Female | 34 (27.0) | 20 (26.0) | 14 (28.6) | |
| Column1 | | | | |
| Male | 92 (73.0) | 57 (74.0) | 35 (71.4) | |
| Age, years | | | | 0.6704 |
| Median (range) | 65 (17-82) | 65 (17-81) | 65 (34-82) | |
| Approach - n (%) | | | | 0.7159 |
| Laparoscopic | 40 (31.7) | 24 (31.2) | 16 (32.7) | |
| Open | 86 (68.3) | 53 (68.8) | 33 (67.3) | |
| Tumor-Diameter (mm) | | | | 0.5462 |
| Minimum | 5 | 5 | 9 | |
| Maximum | 95 | 80 | 95 | |
| Median | 29 | 29 | 29 | |
| Final histology - | | | | |
| n (%) | | | | 0.9902 |
| ccRCC | 84 (66.7) | 52 (67.5) | 32 (65.3) | |
| papRCC | 33 (26.2) | 20 (26.0) | 13 (26.6) | |
| chrRCC | 8 (6.3) | 5 (6.5) | 3 (6.1) | |
| unclassified RCC | 1 (0.8) | | 1 (2.0) | |
| T-Stage - n (%) | | | | 0.8895 |
| 1a | 92 (73.0) | 56 (72.7) | 36 (73.5) | |
| 1b | 28 (22.2) | 17 (22.1) | 11 (22.5) | |
| 2 | 2 (1.6) | 1 (1.3) | 1 (2.0) | |
| 3a | 3 (2.4) | 2 (2.6) | 1 (2.0) | |
| 3b | 1 (0.8) | 1 (1.3) | 0 | |
| Grading - n (%) | | | | 0.6088 |
| 1 | 43 (34.1) | 26 (33.8) | 17 (34.7) | |
| 2 | 77 (61.1) | 47 (61.0) | 30 (61.2) | |
| 3 | 1 (0.8) | 1(1.3) | 0 | |
| 4 | 0 | 0 | 0 | |
| n.a. | 5 (4.0) | 3 (3.9) | 2 (4.1) | |
| Tumor recurrence - | | | | |
| n (%) | | | | |
| Overall | 9 (7.1) | 8 (10.4) | 1 (2.0) | 0.0540 |
| Local | 5 (4.0) | 5 (6.5) | 0 | 0.0245 |

ccRCC, Clear cell renal cell carcinoma; papRCC, papillary renal cell carcinoma; chRCC, chromophobe renal cell carcinoma; n.a., not applicable.

safety margin ≤ 1 mm whereas out of 49 patients with a margin > 1 mm no one developed local recurrence (p=0.0245). Concerning overall recurrence, eight of 77 patients (10.4%) with a benign margin ≤ 1 mm were recurrent whereas only one of 49 patients (2.0%) with a safety margin > 1 mm had RCC relapse (p=0.0540, Figure 2). Univariate and multivariate Cox proportional hazard analysis showed that a safety margin of ≤ 1 mm tends to result in an increased risk for overall recurrence (p=0.0531 and p=0.0539, Table II). There was no correlation between safety margin ≤ 1 mm and CSS or OS (p=0.16 and p=0.97, respectively).




Figure 1. A-F: Partial nephrectomy specimen, A: Macroscopic view. B: Macroscopic view open cut halves. C: Histological whole mount section. D-F: Histological demonstration of different margin widths. C-F: H&E staining, bar upper row=1 cm, bar lower row=200 µm.


Table II. Uni- and multivariate Cox regression analyses concerning local and overall recurrence dependent on margin width ≤1 or >1 mm.

| | Univariate analysis Recurrent disease | | | Multivariate analysis Recurrent disease | | |
|------------------------------|--|-----------|-----------------|--|------------|-----------------|
| Parameters | | | | | | |
| | HR | 95 % CI | <i>p</i> -Value | HR | 95 % CI | <i>p</i> -Value |
| T-Stage, T<3 <i>vs</i> . T≥3 | 0.08 | 0.02-0.59 | 0.0177 | 0.05 | 0.009-0.44 | 0.0102 |
| Grading, G1 vs. G2/3 | 0.65 | 0.17-2.62 | 0.5263 | 0.42 | 0.08-1.93 | 0.2609 |
| Margin width: ≤1 vs. > 1 mm | 0.18 | 0.01-1.01 | 0.0531 | 0.18 | 0.01-1.02 | 0.0539 |

Discussion

The relevance of suspected premalignant lesions within healthy-looking renal tissue outside the pseudocapsule still remains unclear (8-9). The aim of the present study was to investigate whether the tumor adjacent margin width may influence the clinical course of RCC and we found all patients from our collective with locally recurrent disease after NSS showing a margin width of ≤1 mm. Although negative resection margins and an intact pseudocapsule were reported in all investigated specimens, these findings may implicate a correlation of renal parenchymal margin and at least local tumor recurrence. In search for a histological pendant, some reports could give a hint: even in the case of an intact pseudocapsule transboundary

positive cancer lesions have been reported to occur in RCC with an incidence of up to 17% (10). Zucchi *et al.* investigated tumor surrounding benign tissue in patients with RCC and nephronsparing surgery and satellite lesions were identified at a mean of 5.3 mm within the surrounding benign tissue (11). Chen *et al.* were able to show that even in 39% of RCC specimens cancer lesions existed beyond the pseudocapsule within 3 mm of the primary tumor (4). Other authors also reported that a protection from local tumor recurrence cannot be warranted by negative surgical margins in NSS (12). Kwon *et al.* reported local tumor recurrence in four of 713, Permpongkosol *et al.* in 12 of 511 and Antic *et al.* in six of 406 patients even though negative margins were found in the histological examination (12-14). No recurrences were found in patients with low






Figure 2. A-B: Rates of local and overall recurrence in the subgroups with margin width ≤1 and >1 mm. A: Local recurrence, B: overall recurrence.

Table III. Characteristics of patients with local tumor recurrence.

| Age, years | Gender | Surgery | RCC typ | Stage | Grading | Tumor diameter, mm | Bening margin, mm | Time surgery to recurrence, mo |
|------------|--------|--------------|---------|-------|---------|-----------------------|----------------------|--------------------------------|
| 60 | male | laparoscopic | papRCC | T1a | 2 | 8 | ≤ 1 mm | 41 |
| 66 | male | open | ccRCC | T2b | 1 | 50 | ≤ 1 mm | 19 |
| 65 | male | open | ccRCC | T3a | 2 | 44 | ≤ 1 mm | 17 |
| 64 | male | open | ccRCC | T2b | 1 | 50 | ≤ 1 mm | 43 |
| 66 | male | open | ccRCC | T3a | 2 | 63 | ≤ 1 mm | 37 |

malignant tumors in these studies (12-14). In our patients with local recurrence only, two had a higher stage in the final histological report (Table III). Especially Fuhrman nuclear grading was not higher than 2 in these patients. Therefore, based on our findings, local recurrence rates cannot only be explained by RCC with higher malignant potential. In the presented study the benign margin tissue itself was not investigated regarding molecular changes. However, recent data give evidence for molecular alterations in benign looking renal parenchyma leading to precancerous lesions of RCC (8). Arai et al. showed that benign tissue from the renal cortex in RCC-bearing kidneys was in a premalignant stage regarding the DNA methylation status (15). Kanai et al. were able to show that benign tissue in RCC patients is at a precancerous stage and shows DNA methylation alterations (16). Recently, Atschekzei et al. supported this hypothesis by demonstrating significant hypermethylation in benign renal tissue samples from RCC patients compared to benign kidney tissue form patients without RCC and moreover these processes seem to be associated with elevated risk for RCC and even with higher recurrence rates (9). Hence, histologically benign renal tissue in RCC patients may already have a premalignant potential interfering with local recurrence (8-9, 15). These findings are congruent to other malignancies: apart of RCC, in prostate cancer also, molecular alterations were found in peritumoral healthy tissue (6-7). Above this correlation between surgical margin width and recurrence there was no correlation seen to cancer specific or overall survival in the presented data. This might be due to limited number of cases - or this investigated factor is covered by stronger prognostic parameters: Previous studies showed cancer specific survival not to be influenced by the presence of malignant satellite lesions after nephron sparing surgery (11). It has been presumed that survival rates were not associated with resection margin width because of distant metastases following partial nephrectomy are more related to biological aggressiveness of the tumor rather than to the quality of the surrounding tissue (17-18). In this context one possible clinical bias could be excluded: different subtypes of RCC show a different prognosis and more aggressive RCC cancer subtypes are known to have worse clinical outcome than others (19-20). However, our data revealed no differences within the histopathological subtypes between the patients with safety margins of ≤ 1 and > 1 mm.

There are inherent limitations to be stated, such as the limited number of cases and recurrence events, multiple surgeons as well as different surgical approaches performed possibly influencing the benign margin width and outcome of this study. To reduce the impact of these variables on the presented findings further prospective studies with higher number of patients and recurrence events as well as clear defined surgical techniques are need to reach more definitive results. In addition tumor adjacent benign-looking tissue should be investigated in R0-patients were local recurrence was found to assess whether premalignant lesions or processes have already been existent.

However, despite the small study population and the low number of local recurrences a significant result regarding the impact of surgical margins in RCC was observed.

Conclusion

The width of tumor adjacent renal parenchyma may have oncological relevance. Herein, the demonstrated data should point to further molecular studies to clarify the molecular status of this tumor adjacent tissue. These findings then have to be inserted into a topographic context to enable describing molecular conditions in dependence of the histological border of RCC. Finally these results may influence clinical strategies and improve treatment of RCC.

Acknowledgements

The Authors thank Borris Golinski for his technical assistance

References

- 1 Touijer K, Jacqmin D, Kavoussi LR, Montorsi F, Patard JJ, Rogers CG, Russo P, Uzzo RG, and Van Poppel H: The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. Eur Urol 57: 214-222, 2010
- 2 Minervini A, Serni S, Tuccio A, Siena G, Vittori G, Masieri L, Giancane S, Lanciotti M, Khorrami S, Lapini A, and Carini M: Simple enucleation versus radical nephrectomy in the treatment of pT1a and pT1b renal cell carcinoma. Annals of surgical oncology 19: 694-700, 2012.
- 3 Serni S, Vittori G, Frizzi J, Mari A, Siena G, Lapini A, Carini M, and Minervini A: Simple enucleation for the treatment of highly complex renal tumors: Perioperative, functional and oncological results. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 41: 934-940, 2015.
- 4 Chen XS, Zhang ZT, Du J, Bi XC, Sun G, and Yao X: Optimal surgical margin in nephron-sparing surgery for T1b renal cell carcinoma. Urology 79: 836-839, 2012.
- 5 Horstmann M, Merseburger AS, von der Heyde E, Serth J, Wegener G, Mengel M, Feil G, Hennenlotter J, Nagele U, Anastasiadis A, Bokemeyer C, Stenzl A, and Kuczyk M: Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels. J Cancer Res Clin Oncol 131: 715-722, 2005.
- 6 Heni M, Hennenlotter J, Scharpf M, Lutz SZ, Schwentner C, Todenhofer T, Schilling D, Kuhs U, Gerber V, Machicao F, Staiger H, Haring HU, and Stenzl A: Insulin receptor isoforms A and B as well as insulin receptor substrates-1 and -2 are differentially expressed in prostate cancer. PLoS One 7: e50953, 2012.
- 7 Merseburger AS, Hennenlotter J, Simon P, Muller CC, Kuhs U, Knuchel-Clarke R, Moul JW, Stenzl A, and Kuczyk MA: Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncol Rep 16: 79-83, 2006.

- 8 Xu B, Zhang L, Luo C, Qi Y, Cui Y, Ying JM, Zhang Q, and Jin J: Hypermethylation of the 16q23.1 tumor suppressor gene ADAMTS18 in clear cell renal cell carcinoma. International journal of molecular sciences *16*: 1051-1065, 2015.
- 9 Atschekzei F, Hennenlotter J, Janisch S, Grosshennig A, Trankenschuh W, Waalkes S, Peters I, Dork T, Merseburger AS, Stenzl A, Kuczyk MA, and Serth J: SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence. Epigenetics: official journal of the DNA Methylation Society 7: 447-457, 2012.
- 10 Li QL, Guan HW, Zhang LZ, Zhang QP, Wang FP, and Liu YJ: [Optimal margin in nephron-sparing surgery for renal cell carcinoma 4 cm or less in diameter]. Zhonghua wai ke za zhi [Chinese journal of surgery] 41: 81-83, 2003.
- 11 Zucchi A, Mearini L, Mearini E, Costantini E, Vivacqua C, and Porena M: Renal cell carcinoma: histological findings on surgical margins after nephron sparing surgery. J Urol 169: 905-908, 2003.
- 12 Antic T and Taxy JB: Partial nephrectomy for renal tumors: lack of correlation between margin status and local recurrence. Am J Clin Pathol 143: 645-651, 2015.
- 13 Permpongkosol S, Colombo JR, Jr., Gill IS, and Kavoussi LR: Positive surgical parenchymal margin after laparoscopic partial nephrectomy for renal cell carcinoma: oncological outcomes. J Urol 176: 2401-2404, 2006.
- 14 Kwon EO, Carver BS, Snyder ME, and Russo P: Impact of positive surgical margins in patients undergoing partial nephrectomy for renal cortical tumours. BJU Int 99: 286-289, 2007.
- 15 Arai E, Ushijima S, Fujimoto H, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, and Kanai Y: Genomewide DNA methylation profiles in both precancerous conditions and clear cell renal cell carcinomas are correlated with malignant potential and patient outcome. Carcinogenesis 30: 214-221, 2009.
- 16 Kanai Y: Genome-wide DNA methylation profiles in precancerous conditions and cancers. Cancer Sci 101: 36-45, 2010.
- 17 Kang HW, Lee SK, Kim WT, Yun SJ, Lee SC, Kim WJ, Hwang EC, Kang SH, Hong SH, Chung J, Kwon TG, Kim HH, Kwak C, Byun SS, and Kim YJ: Surgical margin does not influence recurrence rate in pT1 clear cell renal cell carcinoma after partial nephrectomy: A multicenter study. J Surgl Oncol, 2016. doi: 10.1002/jso.24259. [Epub ahead of print]
- 18 Kubinski DJ, Clark PE, Assimos DG, and Hall MC: Utility of frozen section analysis of resection margins during partial nephrectomy. Urology 64: 31-34, 2004.
- 19 Steffens S, Janssen M, Roos FC, Becker F, Schumacher S, Seidel C, Wegener G, Thuroff JW, Hofmann R, Stockle M, Siemer S, Schrader M, Hartmann A, Kuczyk MA, Junker K, and Schrader AJ: Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study. Eur J Cancer 48: 2347-2352, 2012.
- 20 Zhang Y and He H: [Histologic subtyping and clinicopathologic features of papillary renal cell carcinoma]. Zhonghua bing li xue za zhi Chinese journal of pathology 44: 761-766, 2015.

Received April 3, 2016 Revised May 9, 2016 Accepted May 17, 2016